The FY22 VRP TRA is intended to support translational research that moves promising discoveries into clinical applications that will advance the prevention, diagnosis, mitigation, and/or treatment of eye injury or visual dysfunction associated with military exposure.

Successful applications to the FY22 VRP TRA should establish a clear path to transforming a promising discovery into new drugs, devices, or clinical practice guidelines that are ready for definitive testing in clinical trials. It is expected that, if applicable, an Investigational New Drug (IND)/ Investigational Device Exemption (IDE) application will be submitted during or by the end of the period of performance. For new drug or device development, the investigative team should include at least one collaborator with expertise in the U.S. Food and Drug Administration (FDA) regulatory approval process.